News

American Lung Association3d

Massachusetts Researcher Awarded American Lung Association and CHEST Grant to Study Community Air Pollution Exposure and COPD

The American College of Chest Physicians (CHEST) and the American Lung Association (ALA) have awarded the CHEST/ALA Guideline Implementation Research Grant for Chronic Obstructive Pulmonary Disease ...
American Lung Association3d

Lung Health Champions Converge on Capitol Hill to Protect Lifesaving Care, Coverage and Federal Public Health Programs

On September 10, the American Lung Association will host its third Respiratory Advocacy Day, bringing together patient advocates living with lung disease in Washington, D.C., to share their personal ...
Healio16h

More severe cough found in adults with undiagnosed COPD, asthma vs. normal spirometry

Among adults with undiagnosed respiratory symptoms, those with undiagnosed COPD and asthma vs. preserved ratio impaired or ...

FANSS study demonstrates feasibility of U.S.-based lung cancer screening in Asian female nonsmokers

Results from the Female Asian Nonsmoker Screening Study (FANSS) highlight the potential value of low-dose CT (LDCT) screening ...

Emphysema at CT lung screening linked to higher risk of death in asymptomatic adults

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic ...
Medindia6d

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

Johnson & Johnson (NYSE:JNJ) today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) significantly ...

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line ...

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year ...